Abstract
Alteration in the expression of invasion/metastasis-related melanoma cell adhesion molecule (MelCAM) is strongly associated with the acquisition of malignancy by human melanoma. However, little is known about the molecular and biochemical mechanisms that regulate the expression and function of MelCAM, or its downstream signaling transduction. In this study, we show that there is a reciprocal regulation loop between AKT and MelCAM. Pharmacological inhibition of AKT in human melanoma cell lines substantially reduced the expression of MelCAM. Overexpression of constitutively active AKT upregulated the levels of MelCAM in melanoma cell lines, whereas expression of a dominant-negative PI-3 kinase downregulated MelCAM. On the other hand, overexpression of MelCAM activated endogenous AKT and inhibited proapoptotic protein BAD in melanoma cells, leading to increased survival under stress conditions. Constitutive activation of AKT was observed in most melanoma cell lines and tumor samples of different progression stages. These data link AKT activation with MelCAM expression, and implicate that intervention of MelCAM-AKT signaling axis in melanoma is a potential therapeutical approach.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M and Buck CA . (1990). Cancer Res., 50, 6757–6764.
Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M, Cron P, Cohen P, Lucocq JM and Hemmings BA . (1997). J. Biol. Chem., 272, 31515–31524.
Anfosso F, Bardin N, Frances V, Vivier E, Camoin-Jau L, Sampol J and Dignat-George F . (1998). J. Biol. Chem., 273, 26852–26856.
Aoki M, Batista O, Bellacosa A, Tsichlis P and Vogt PK . (1998). Proc. Natl. Acad. Sci. USA, 95, 14950–14955.
Armstrong PB . (1989). Crit. Rev. Biochem. Mol. Biol., 24, 119–149.
Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, Stokoe D, McCormick F, Feng J and Tsichlis P . (1998). Oncogene, 17, 313–325.
Bellacosa A, Testa JR, Staal SP and Tsichlis PN . (1991). Science, 254, 274–277.
Berking C and Herlyn M . (2001). Histol. Histopathol., 16, 669–674.
Bissell MJ and Radisky D . (2001). Nat. Rev., 1, 46–54.
Blume-Jensen P and Hunter T . (2001). Nature, 411, 355–365.
Datta SR, Brunet A and Greenberg ME . (1999). Genes Dev., 13, 2905–2927.
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME . (1997). Cell, 91, 231–241.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA . (2002). Nature, 417, 949–954.
Diehl JA, Cheng M, Roussel MF and Sherr CJ . (1998). Genes Dev., 12, 3499–3511.
Downward J . (1998). Curr. Opin. Cell Biol., 10, 262–267.
Folberg R, Hendrix MJ and Maniotis AJ . (2000). Am. J. Pathol., 156, 361–381.
Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, Schatteman GC and Seftor RE . (2001). Proc. Natl. Acad. Sci. USA, 98, 8018–8023.
Hess AR, Seftor EA, Gardner LM, Carles-Kinch K, Schneider GB, Seftor RE, Kinch MS and Hendrix MJ . (2001). Cancer Res., 61, 3250–3255.
Hsu M, Andl T, Li G, Meinkoth JL and Herlyn M . (2000a). J. Cell Sci., 113, 1535–1542.
Hsu M-Y, Elder DE and Herlyn M . (1999). Human Cell Culture Vol. 3. Palsson JMaB (ed.) Kluwer Academic Publishers: London pp 259–274.
Hsu MY, Meier FE, Nesbit M, Hsu JY, Van Belle P, Elder DE and Herlyn M . (2000b). Am. J. Pathol., 156, 1515–1525.
Hsu MY, Shih DT, Meier FE, Van Belle P, Hsu JY, Elder DE, Buck CA and Herlyn M . (1998). Am. J. Pathol., 153, 1435–1442.
Jean D, Gershenwald JE, Huang S, Luca M, Hudson MJ, Tainsky MA and Bar-Eli M . (1998). J. Biol. Chem., 273, 16501–16508.
Johnson JP . (1992). Int. J. Clin. Lab. Res., 22, 69–72.
Johnson JP . (1999). Cancer Metastasis Rev., 18, 345–357.
Johnson JP, Bar-Eli M, Jansen B and Markhof E . (1997). Int. J. Cancer, 73, 769–774.
Johnson JP, Rothbacher U and Sers C . (1993). Melanoma Res., 3, 337–340.
Kassenbrock CK, Hunter S, Garl P, Johnson GL and Anderson SM . (2002). J. Biol. Chem., 277, 24967–24975.
Kohn AD, Takeuchi F and Roth RA . (1996). J. Biol. Chem., 271, 21920–21926.
Kotani K, Ogawa W, Hino Y, Kitamura T, Ueno H, Sano W, Sutherland C, Granner DK and Kasuga M . (1999). J. Biol. Chem., 274, 21305–21312.
Lehmann JM, Holzmann B, Breitbart EW, Schmiegelow P, Riethmuller G and Johnson JP . (1987). Cancer Res., 47, 841–845.
Li G and Herlyn M . (2000). Mol. Med. Today, 6, 163–169.
Li G, Satyamoorthy K and Herlyn M . (2001a). Cancer Res., 61, 3819–3825.
Li G, Satyamoorthy K and Herlyn M . (2002). Crit. Rev. Oral Biol. Med., 13, 62–70.
Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K and Herlyn M . (2001b). Oncogene, 20, 8125–8135.
Liu YC and Altman A . (1998). Cell Signal, 10, 377–385.
Luca M, Hunt B, Bucana CD, Johnson JP, Fidler IJ and Bar-Eli M . (1993). Melanoma Res., 3, 35–41.
Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS and Hendrix MJ . (1999). Am. J. Pathol., 155, 739–752.
Meier F, Nesbit M, Hsu MY, Martin B, Van Belle P, Elder DE, Schaumburg-Lever G, Garbe C, Walz TM, Donatien P, Crombleholme TM and Herlyn M . (2000). Am. J. Pathol., 156, 193–200.
Mills L, Tellez C, Huang S, Baker C, McCarty M, Green L, Gudas JM, Feng X and Bar-Eli M . (2002). Cancer Res., 62, 5106–5114.
Nicholson KM and Anderson NG . (2002). Cell. Signal., 14, 381–395.
Oka M, Nagai H, Ando H, Fukunaga M, Matsumura M, Araki K, Ogawa W, Miki T, Sakaue M, Tsukamoto K, Konishi H, Kikkawa U and Ichihashi M . (2000). J. Invest. Dermatol., 115, 699–703.
Parker SL, Tong T, Bolden S and Wingo PA . (1997). CA Cancer J. Clin., 47, 5–27.
Poetsch M, Dittberner T and Woenckhaus C . (2001). Cancer Genet. Cytogenet., 125, 21–26.
Pollock PM and Trent JM . (2000). Clin. Lab. Med., 20, 667–690.
Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK, Rosenberg HM, Vernon SW, Cronin K and Edwards BK . (2000). Cancer, 88, 2398–2424.
Rudd CE . (1999). Cell, 96, 5–8.
Rummel MM, Sers C and Johnson JP . (1996). Cancer Res., 56, 2218–2223.
Sakaue H, Ogawa W, Takata M, Kuroda S, Kotani K, Matsumoto M, Sakaue M, Nishio S, Ueno H and Kasuga M . (1997). Mol. Endocrinol., 11, 1552–1562.
Satyamoorthy K, DeJesus E, Linnenbach AJ, Kraj B, Kornreich DL, Rendle S, Elder DE and Herlyn M . (1997). Melanoma Res., 7, (suppl. 2) S35–S42.
Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, van Belle P, Elder DE and Herlyn M . (2003). Cancer Res., 63, 756–759.
Satyamoorthy K, Li G, Vaidya B, Patel D and Herlyn M . (2001a). Cancer Res., 61, 7318–7324.
Satyamoorthy K, Muyrers J, Meier F, Patel D and Herlyn M . (2001b). Oncogene, 20, 4676–4684.
Sers C, Kirsch K, Rothbacher U, Riethmuller G and Johnson JP . (1993). Proc. Natl. Acad. Sci. USA, 90, 8514–8518.
Shih IM . (1999). J. Pathol., 189, 4–11.
Shih IM, Elder DE, Hsu MY and Herlyn M . (1994a). Am. J. Pathol., 145, 837–845.
Shih IM, Elder DE, Speicher D, Johnson JP and Herlyn M . (1994b). Cancer Res., 54, 2514–2520.
Shih IM, Speicher D, Hsu MY, Levine E and Herlyn M . (1997). Cancer Res., 57, 3835–3840.
Shiojima I and Walsh K . (2002). Circ. Res., 90, 1243–1250.
Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW and Liao JK . (2000). Nature, 407, 538–541.
Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV and Cheng JQ . (2001). Cancer Res., 61, 5985–5991.
Vivanco I and Sawyers CL . (2002). Nat. Rev. Cancer, 2, 489–501.
Waldmann V, Wacker J and Deichmann M . (2001). Arch. Dermatol. Res., 293, 368–372.
Waldmann V, Wacker J and Deichmann M . (2002). Melanoma Res., 12, 45–50.
White MF and Kahn CR . (1994). J. Biol. Chem., 269, 1–4.
Woods D, Cherwinski H, Venetsanakos E, Bhat A, Gysin S, Humbert M, Bray PF, Saylor VL and McMahon M . (2001). Mol. Cell. Biol., 21, 3192–3205.
Xie S, Luca M, Huang S, Gutman M, Reich R, Johnson JP and Bar-Eli M . (1997). Cancer Res., 57, 2295–2303.
Acknowledgements
We thank all members of Herlyn lab for technical and intellectual support. This work was supported by the National Institutes of Health Grants CA-25874, CA-76674, CA-47159, CA-80999 and CA-10815.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, G., Kalabis, J., Xu, X. et al. Reciprocal regulation of MelCAM and AKT in human melanoma. Oncogene 22, 6891–6899 (2003). https://doi.org/10.1038/sj.onc.1206819
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206819
Keywords
This article is cited by
-
CD146 T cells in lung cancer: its function, detection, and clinical implications as a biomarker and therapeutic target
Cancer Cell International (2019)
-
Prolonged DADLE exposure epigenetically promotes Bcl-2 expression and elicits neuroprotection in primary rat cortical neurons via the PI3K/Akt/NF-κB pathway
Acta Pharmacologica Sinica (2018)
-
The multifaceted role of CD146/MCAM in the promotion of melanoma progression
Cancer Cell International (2015)
-
The membrane protein melanoma cell adhesion molecule (MCAM) is a novel tumor marker that stimulates tumorigenesis in hepatocellular carcinoma
Oncogene (2015)
-
Semaphorin 3A upregulates FOXO 3a-dependent MelCAM expression leading to attenuation of breast tumor growth and angiogenesis
Oncogene (2015)